Pirchio, R.
Auriemma, R. S.
Montini, M. E.
Vergura, A.
Pivonello, R.
Colao, A. http://orcid.org/0000-0003-4049-2559
Funding for this research was provided by:
Università degli Studi di Napoli Federico II
Article History
Received: 21 July 2022
Accepted: 1 December 2022
First Online: 9 March 2023
Declarations
:
: RP, RSA, MEM, AV declare they have no financial interests. AC has been Principal Investigator of Research Studies for Novartis, Ipsen, Pfizer, Lilly, Merck and Novo Nordisk; consultant for Novartis, Ipsen, Pfizer, and received honoraria from Novartis, Ipsen and Pfizer beyond the confines of this work. RPiv has been Principal Investigator of Clinical and/or Translational Research Studies for Novartis, HRA Pharma, Ipsen, Shire, Corcept Therapeutics, Cortendo AB, Janssen Cilag, Camurus, Strongbridge, and Pfizer; Co-investigator of Research Studies for Pfizer; received research grants from Novartis, Pfizer, Ipsen, HRA Pharma, Shire, IBSA, Strongbridge Biopharma; has been an occasional consultant for Novartis, Ipsen, Pfizer, Shire, HRA Pharma, Cortendo AB, Ferring, Strongbridge Biopharma, Recordati, Corcept Therapeutics, Crinetics Pharmaceuticals, ARH Healthcare, Biohealth Italia; and has received fees and honoraria for presentations from Novartis, Shire, Pfizer and Recordati beyond the confines of this work.
: Approval was obtained from the ethics committee of “FedericoII” University (amendment 27/06/2002). The procedures used in this study adhere to the tenets of the Declaration of Helsinki.
: Informed consent was obtained from all individual participants included in the study.